Implementing ctDNA and Circular DNA in Patients With Localized Pancreatic Cancer
Recruiting
N/A
Interventional Study
Resectable Pancreatic Cancer
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
At a Glance
- Sex
- Any
- Study type
- Interventional
- Purpose
- Basic Science
- Participants needed
- 1,000 (estimated)
- Sponsor
- Copenhagen University Hospital at Herlev · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
The goal of this clinical trial is to investigate if plasma ctDNA and eccDNA before resection for suspicion of pancreatic ductal adenocarcinoma (PDAC) can predict early recurrence and overall survival, and to investigate if plasma ctDNA combined with CT scan and endoscopic ultrasound surveillance increases the median overall survival compared with standard-of-care surveillance.
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* Sub-study 1: Suspicion of PDAC tumor stage I-III, scheduled for pancreatic resection, with or without preoperative neoadjuvant chemotherapy.
* Sub-study 2: .
* PDAC tumor stage I-III
* Has received intended curative resection (R0/R1) of PDAC
* No signs of local recurren…
Contacts